We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stem Cell Model of a Severe Epilepsy Syndrome Identifies a Potential Targeted Treatment

Stem cells.
Credit: doodlartdotcom / Pixabay.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Mutations in the SCN3A gene cause a spectrum of neurological conditions collectively referred to as SCN3A-related neurodevelopmental disorders, which includes different types of epilepsy and brain malformations. In a new study from researchers at Children’s Hospital of Philadelphia (CHOP), human induced pluripotent stem cell (IPSC) technology and gene editing were used to model SCN3A disorders, establish mechanisms of abnormal neuronal function, and identify a pharmacologic agent that selectively blocks the channel that could represent a potential therapeutic option for these patients in the future.

The findings were recently published online by the journal Brain.

The SCN3A gene encodes the instructions to form a sodium channel, which is a protein complex that allows positively charged sodium ions into brain cells that activate neurons to carry electrical signals between brain cells throughout the brain and our nervous system. However, missense variants – resulting from single base pair changes in DNA that lead to switched amino acids– can affect a sodium channel subunit called Nav1.3, leading to early onset and severe epilepsy as well as structural malformation in the development of the cerebral cortex of the brain.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Despite knowing which subunit and variants are associated with SCN3A-related neurodevelopmental disorders, the mechanisms of how they lead to disease symptoms was unclear. To help unravel this mystery, researchers used human IPSC technology and CRISPR/Cas9 gene editing to compare human neurons harboring disease-associated SCN3A variants as well as so-called isogenic controls with normal sodium channels to study how SCN3A controls the electrical activity of early brain neurons and how SCN3A mutations alters activity of developing neurons.

The researchers were able to develop forebrain-like neurons from IPSCs (iNeurons) that expressed the variant Nav1.3-mediated sodium ion currents as well as control iNeurons. With this method, the researchers found that the modified iNeurons expressing the variant had increased slowly-inactivating (“persistent”) sodium ion currents that led to abnormal neuron firing patterns.

To test whether the Nav1.3 subunit might be a therapeutic target for potential treatments for this group of disorders, the researchers tested a Nav1.3-selective blocker. They found that after the blocker was applied, abnormal neuronal activity was restored to normal.

Reference: Qu G, Merchant JP, Clatot J, et al. Targeted blockade of aberrant sodium current in a stem cell-derived neuron model of SCN3A encephalopathy. Brain. 2023:awad376. doi: 10.1093/brain/awad376

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.